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Introduction
Vitamin D is widely recognised as essential for normal 
skeletal metabolism. In childhood, maintenance of sufficient 
serum 25-hydroxyvitamin D (25OHD) levels is critical 
Abstract
The Maternal Vitamin D Osteoporosis (MAVIDOS) trial reported higher total body bone mineral content in 
winter-born infants of mothers receiving vitamin D supplementation [1000 IU/day cholecalciferol] compared with 
placebo from 14 weeks gestation until delivery. This sub-study aimed to determine whether antenatal vitamin D 
supplementation altered postnatal bone formation in response to mechanical stimulation. Thirty-one children born to 
MAVIDOS participants randomised to either placebo (n=19) or cholecalciferol (n=12) were recruited at age 4-5 years. 
Children received whole body vibration (WBV) for 10 minutes on 5 consecutive days. Fasting blood samples for bone 
homeostasis, 25 hydroxyvitamin D (25OHD), parathyroid hormone (PTH), and bone turnover markers (Pro-collagen 
Type 1 N-terminal propeptide, P1NP; Cross-linked C-telopeptide of Type I Collagen, CTX) were collected pre-WBV and 
on day 8 (D8). Mean changes (D) in P1NP (ng/ml) between baseline and D8 in the vitamin-D intervention and placebo 
groups were 40.6 and -92.6 respectively and mean changes (Δ) in CTX (ng/ml) were 0.034 (intervention) and -0.084 
(placebo) respectively. Between-group DP1NP difference was 133.2ng/ml [95% CI 0.4, 266.0; p=0.049] and ΔCTX 
0.05ng/ml (95% CI -0.159, 0.26ng/mL; p=0.62). Antenatal vitamin-D supplementation resulted in increased P1NP 
in response to WBV, suggesting early life vitamin D supplementation increases the anabolic response of bone to 
mechanical loading in children.
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to prevent adverse outcomes, including hypocalcaemic 
seizures, cardiomyopathy, rickets and growth failure. 
There is also increasing recognition that maternal vitamin 
D status might be an important determinant of offspring 
bone development2-4. Lower bone mass accrual in childhood 
resulting in bones that are of reduced size in relation to body 
size is predictive of increased fracture risk5. Observational 
studies have demonstrated that lower maternal serum 
25OHD during pregnancy and at birth are associated with 
reduced bone width and mass in the offspring at 8-9 years 
age6. The Southampton Women’s Survey also reported a 
positive correlation between maternal 25OHD status and 
offspring bone mineral accrual7 at age 6-7 years8. The 
study from the Australian Raine Cohort demonstrated a 
positive relationship between maternal vitamin D status 
and offspring bone mass at 20 years9. Equally there are 
observational data that do not support these findings10. 
The ALSPAC study demonstrated no association between 
maternal vitamin D status and offspring bone mass at 9 
years11. Similarly, Garcia et al. reported no association 
between maternal 25OHD concentrations in mid-pregnancy 
and offspring bone mineral density12.
The Maternal Vitamin D Osteoporosis Study (MAVIDOS), 
a multicentre, randomised, double-blind, placebo controlled 
trial of 1000 IU/day cholecalciferol vs. placebo from 
14 weeks gestation to birth, was conducted at three UK 
centres (Southampton, Oxford and Sheffield)4. Although no 
significant differences in neonatal bone indices (bone area, 
bone mineral content (BMC), bone mineral density (BMD)) 
were detected between randomization groups overall, in a 
pre-specified analysis, an interaction between treatment 
group and offspring season of birth was detected. Whole 
body BMC and BMD were shown to be approximately 9% and 
5% higher, respectively, in children born in winter (December 
to February) to mothers randomised to cholecalciferol 
compared to those randomised to placebo, a difference in 
BMC of around 0.5 standard deviations (p=0.004)1. 
The growing skeleton responds to mechanical stimulation 
with an increase in bone size and mass and that can persist 
into adult life13,14. In contrast, without mechanical stimulation, 
peak bone mass may not be fully achieved15,16. Data from 
our preclinical murine model study looking at the effect of 
reduced vitamin D intake during pregnancy and early life on 
the skeleton’s response to mechanical loading demonstrated 
that antenatal vitamin D depletion substantially reduces the 
loading-dependent increase in both cortical and trabecular 
bone mass of offspring mice17. We have also demonstrated 
in a cohort of healthy pre-pubertal boys aged between 9 and 
11 years, that brief exposure to whole body vibration - 10 
minutes daily for five days - increases the bone formation 
marker N-terminal propeptide of type I procollagen (PINP) by 
25% and the bone resorption marker C-terminal telopeptide 
of type I collagen (CTX) by 11%18.
The main aim of our study was to investigate whether 
antenatal vitamin D supplementation altered postnatal 
bone formation in response to mechanical stimulation by 
WBV. Our hypothesis was that children born to mothers 
who received vitamin D supplementation during pregnancy 
would have a greater increase in the bone formation marker 
P1NP in response to WBV than children whose mothers had 
received placebo.
Materials and methods
Study design
This was a prospective single centre interventional study 
in which each subject participated in the trial for a total of 8 
days. The study sample consisted of children born to mothers 
who had participated in the MAVIDOS study. Details of the 
MAVIDOS study have been published previously1,4, but briefly, 
women with a baseline 25(OH)D between 25 and 100 nmol/l 
at 11-14 weeks’ gestation were randomized to either placebo 
or 1000 IU/day cholecalciferol from 14 weeks gestation until 
delivery (n=1134). Women were recruited into the MAVIDOS 
study from three UK centres: Southampton, Oxford and 
Sheffield. All children born to mothers who participated in 
MAVIDOS trial in Sheffield (n=56) were invited to participate 
in this sub-study.
Prior to undertaking this study, we conducted a patient and 
public involvement (PPI) focus group. A total of six mothers 
from various occupational backgrounds ranging from 
homemaker to a mathematician took part in the focus group. 
A copy of the lay summary, patient information leaflet(s) and 
the consent form has been forwarded to all the volunteers 
48 hours prior to the meeting. All the six volunteers actively 
took part in the discussion and shared their comments, views 
and suggestions openly to the group. They made suggestions 
to the wordings of the participant information sheet, timings 
and place of tests that are more comfortable for young 
children. We based our focus group discussion from our 
earlier work in this area18.
All potential participants were contacted by methods 
discussed and agreed by the patient and public involvement 
(PPI) focus group of this study. Information sheets detailing 
the study procedures with our contact details were sent out 
to the families of potential participants who had expressed an 
interest in the study prior to their attendance. Parents and 
families were clearly informed that this study was an additional 
study to MAVIDOS, so they were free to decline without their 
participation in the core trial protocol being affected.
The Yorkshire and Humber South Yorkshire Research 
Ethics Committee approved the study. Written informed 
consent was obtained from the parents and guardians of all 
study participants. The ClinicalTrials.gov registration number 
is NCT02743559. 
Study participants
There were a total of 56 potential participants. The children 
were aged between 4 and 5 years at the time of recruitment 
and they formed 2 groups, (i) an intervention group whose 
mothers had received antenatal vitamin D (cholecalciferol 
1000 IU/day) supplements (n=29) and (ii) a placebo group 
(n=27) (Figure 1). 
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Children with balance problems, existing or healing 
fractures, any chronic illness involving bone, liver or renal 
systems, with known disorders of growth or glucose 
metabolism, or with existing long-term use of steroids, 
anticonvulsants or any medication that might affect calcium 
and vitamin D metabolism were excluded. 
Enrolment into the study and first day procedures 
took place in the Clinical Research Facility at Sheffield 
Children’s Hospital; other study procedures took place at the 
participant’s home. 
Anthropometry, activity and diet
Anthropometry was undertaken with the participants 
wearing light clothing (vest and pants). Height (without shoes, 
to next succeeding 1 mm) by wall-mounted stadiometer 
(Holtain, Crymych), and weight (to nearest 0.1 kg) by electronic 
balance scales (Seca GmbH & Co, Hamburg, Germany) were 
measured. Body mass index (BMI) was derived as [weight 
(kg)/height (m)2]. A validated questionnaire regarding 
exercise19 was used to ascertain the amount of physical 
activity undertaken over the 7 days prior to standing on 
the platform and then again on day 8 to determine whether 
undergoing WBV had had an effect on participant’s levels of 
physical activity. The frequency and intensity of the types of 
exercise given in answer to these questions were multiplied 
by the anticipated metabolic equivalents (METs) of nine, 
five and three for strenuous, moderate, and mild exercise 
respectively, to provide an activity score for comparison. The 
“Rapid assessment of dietary calcium intake” questionnaire 
was given to all participants and their parents/carers20.
Laboratory methods
Fasting blood samples for bone homeostasis: calcium, 
phosphorus, alkaline phosphatase, magnesium, PTH, 
serum 25OHD; and for bone turnover markers (P1NP, 
CTX); were collected immediately pre-vibration on day 1 
and again on day 8.
Serum calcium, phosphate, albumin, and alkaline 
phosphatase were measured using Micro Slide Technology 
Colorimetric/Rate by Reflectance Spectrophotometry in the 
Vitros 5, 1 FS System (Ortho Clinical Diagnostics; Raritan, 
New Jersey) analyser. The interassay CVs were: calcium 
(1.4%), phosphate (1.6%), albumin (2.9%), and alkaline 
phosphatase (2.4%). Intact parathyroid hormone (PTH) 
was measured using Immunoassay (Chemiluminescent 
Microparticle Immunoassay) in the Architect i 1000 System 
(Abbott; Abbott Park, Illinois) (PTH analytical sensitivity 
≤1 ng/L). Serum total 25-hydroxyvitamin D (25OHD) 
levels were determined using an UPLC/Mass Spectrometer 
Semi-automated hexane extraction in the Acquity Ultra 
Performance LC/Quattro MS (Waters; Milford, Massachusetts) 
analyser. Lower limit of detection for 25OHD
2
 was 6 nmol/L 
and for 25OHD
3
 3.5 nmol/L. The interassay coefficient of 
variation (CV) for 25OHD
2
 and 25OHD
3
 were 5.7% and 5.4% 
respectively. Blood samples for bone formation marker P1NP 
was measured using automated immunoassay (Elecsys, 
Cobas E11, Roche Diagnostics, UK; intraassay % CV<1.7%) 
and bone resorption marker CTX (Elecsys β-CrossLaps/
serum kit, Cobas E411, Roche Diagnostics, UK; intraassay % 
CV 2.8-8.4%). All samples were collected in the mornings 
approximately between 0800 and 0900 hours following 
an overnight fast. Samples were centrifuged, separated and 
stored at -80°C within 2 hours of collection. 
Whole body vibration intervention
The participants were asked to stand barefoot and facing 
forwards on a portable Marodyne LivMD low magnitude 
(0.4g), high frequency (30-90 Hz) vibrating platform 
(Marodyne Medical, Inc., Lakeland, Florida) to receive whole 
body vibration (WBV). WBV was delivered in 4 cycles of 2 
minutes 30 seconds each, separated by 30 seconds off the 
Figure 1. Study design.
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platform, providing 10 minutes of vibration every day for 
5 consecutive days around the same time between 7 and 
8 am. Both participants and their carers were taught to 
use the vibrating plate at home. Delivering vibration in this 
pattern allowed the participants to become accustomed to 
the platform in a more comfortable manner. Additionally, it 
has also been demonstrated that insertion of rest periods 
enhances the anabolic effect of loading on bone21,22. 
Statistical analysis
Sample size was estimated using the results from our 
previous WBV study done on healthy pre-pubertal boys, 
in which a mean difference of 175.6 (SD=162.7) in PINP 
between day 0 and day 8 was found18. To detect 50% of the 
difference in PINP between children of mothers who were 
deficient in vitamin D versus those replete in pregnancy, at 
the 5% significance level with 90% power, would require 20 
observations at day 8 (10 per group). 
We performed all our analyses using Statistical Package 
for the Social Sciences version 22 (SPSS by IBM), Data 
DeskTM v6.2.1, and Stata v1523. Groups were compared at 
baseline using either t-test (continuously distributed data) 
or proportions test (categorical data). Baseline data are 
summarized by median (25th/75th centiles) for continuously 
distributed data or n (%) for categorical data. Graphical 
presentation of bone turnover markers (P1NP and CTX) 
was illustrated using box and whisker plots, which have the 
following interpretation. The median is shown as the middle 
of the box, the 75th centile the top of the box, the 25th centile 
the lower of the box. Whiskers (above and below) the box 
represent values outside the main distribution. Outliers 
are shown as circles. Differences (post vibration - baseline) 
between randomised groups (intervention i.e vitamin D 
supplementation in pregnancy vs placebo) for PTH, 25OHD, 
bone profile, and bone turnover markers were analysed by an 
independent t-test using an arbitrary level of 5% statistical 
significance (two-tailed). Ninety five percent (95%) 
confidence intervals (CIs) were estimated. 
Results
31 children (placebo group n=19; cholecalciferol group 
n=11) participated in the study. Baseline characteristics of the 
study subjects are shown in Table 1. Age, gender, ethnicity, 
height, weight, and BMI were similar between the groups. 
Bone profile including serum 25OHD and PTH were normal 
in the entire cohort and there were no significant differences 
between the groups. 
Data acquisition on diet and exercise shown in Table 1 were 
limited due to non-filling of questionnaires or failed recall 
of requested information in 30% of cases (similar in both 
groups). Dietary calcium intake (grams/day) was significantly 
higher in the intervention group (p=0.04). The activity score 
(METs units) was significantly higher in the placebo group 
when compared with the intervention group (p=0.04). 
Median (25th/75th centiles) P1NP (ng/ml) at baseline was 
552.2 (512.3, 678.6) for the intervention group and 587.1 
(518.2, 801.7) for the placebo group. Comparison of P1NP 
at baseline and post vibration by randomisation group is 
shown in Figure 2. The mean change (Δ) in P1NP (ng/ml) 
between baseline and D8 in the intervention and placebo 
groups was 40.6 and -92.6, respectively. The between-
able 1. Baseline characteristics. Data are median (25th/75th centiles) or n (%). Bold type indicates significant p value.
Variable Intervention Placebo p value
Age (years) 4.9(4.4,5.2) 5.1(4.5,5.4) 0.318
Gender (female) 7(58%) 8(42%) 0.295
Ethnicity (caucasian) 12(100%) 14(74%) 0.21
Height (cms) 107.5(102.5, 113.4) 108.1 (103.8, 114) 0.43
Weight (kg) 18.3 (16.9, 21.7) 17.8 (16.2, 18.8) 0.68
BMI (kg/m2) 16.1 (15.7, 17.0) 15.0 (14.1, 16.2) 0.16
Serum 25OHD (nmol/l) 71(58,98) 79(61,81) 0.537
Serum calcium (mmol/l) 2.4(2.37,2.42) 2.35(2.31,2.42) 0.615
Serum phosphate (mmol/l) 1.52(1.5,1.62) 1.61(1.55,1.69) 0.058
Serum alkaline Phosphatase (u/l) 204.5(180,215) 200(186,213) 0.864
Serum albumin (g/l) 42(41,44) 42(41.5,43.5) 0.634
Serum magnesium (mmol/l) 0.85(0.85,0.89) 0.84(0.82,0.88) 0.379
Serum parathyroid hormone (ng/l) 27.9(24.0,34.1) 36.5(22.3,40.0) 0.685
Serum P1NP (ng/ml) 552.2(512.3,678.6) 587.1(518.2,801.7) 0.558
Serum CTX (ng/ml) 1.52(1.3,1.81) 1.59(1.3,1.81) 0.618
Dietary calcium intake (gms/day) 783(577,842) 521(430,535) 0.040
Activity score (METS units) 66 (44,83) 104 (68,120) 0.040
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group difference in ΔP1NP was 133.2 ng/mL (95% CI 
0.4, 266.0; p=0.049). Mean (%) change in P1NP within 
the intervention group was 11% (pre vs post vibration 
by patient) and within the placebo group was -13.3%; 
difference between groups 24% (Table 2). 
Median (25th/75th centiles) for CTX (ng/mL) at baseline 
was 1.52 (1.3, 1.8) for the intervention group and 1.59 (1.3, 
1.8) and for the placebo group. Comparison of CTX at baseline 
and post vibration by randomisation group is shown in Figure 
3. The mean change (Δ) in CTX (ng/ml) between baseline and 
D8 in the intervention and placebo groups was -0.034 and 
-0.084 ng/ml, respectively. The between-group difference 
in ΔCTX was 0.05 ng/ml (95% CI= -0.159,0.26 ng/mL; 
p=0.62). Mean (%) change in CTX within the intervention 
group was -0.5% and within the placebo group was -4.9%; 
difference between groups 4.4% (Table 2).
Discussion
In this study we have shown that antenatal vitamin 
D supplementation increases the anabolic response of 
growing bone to mechanical stimulation. We found that five 
consecutive days of low magnitude high frequency WBV 
increased the bone formation marker PINP by 11% between 
the pre-vibration baseline and the day 8 measurement in 
children whose mothers had received 1000 IU vitamin D 
Figure 2. P1NP at baseline and post vibration.
Table 2. Comparison of bone turnover markers at baseline and post vibration by randomisation group. Data are median (25th/75th centiles) 
or n (%). Bold type indicates significant p value.
Variable Intervention Placebo 
Between group difference 
(95% confidence interval)
P value
Median serum P1NP (ng/ml) at baseline 552.2(512.3,678.6) 587.1(518.2,801.7) - 0.558
Mean change in P1NP (ng/ml) between 
baseline and D8
40.6 -92.6 133.2 (0.4, 266.0) 0.049
Mean % change in P1NP between baseline 
and D8
11 -13.3 24 -
Median serum CTX (ng/ml) at baseline 1.52(1.3,1.8) 1.59(1.3,1.8) - 0.618
Mean change in CTX (ng/ml) between 
baseline and D8
-0.034 -0.084 0.05 (-0.159,0.26) 0.620
Mean % change in CTX between baseline 
and D8
-0.5 -4.9 4.4 -
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supplementation during pregnancy. By contrast the P1NP 
decreased by 13% in the placebo group, showing a net benefit 
of 24% in the intervention group. We did not find a change in 
the bone resorption marker CTX in either the intervention or 
the placebo group. 
These results are in contrast to the findings of our 
previous study in which the effect of WBV in 36 healthy 
pre pubertal boys was examined. Participants in that study 
received either low (<1 g, frequency 32-37 Hz, amplitude 
0.085 mm) or high (>2 g, frequency 5 to 30 Hz, amplitude 
0+/-4.5 mm) magnitude vibration for 1, 3 or 5 consecutive 
days. A significant rise in both P1NP 25.1% (p=0.005) and 
CTX 10.9% (p=0.009) from baseline to day 8 was observed 
in the group exposed to 5 days of WBV, irrespective of the 
mode of vibration18. However, subjects in that study were 
older (9-11 years) and had higher baseline P1NP and CTX 
levels. It is possible some of those participants, despite being 
Tanner stage 1, had some early hormonal changes of puberty 
resulting in a higher P1NP and CTX response to vibration. 
It may also be the case that there were simply insufficient 
numbers in this study to detect significant changes in CTX.
The increase in the bone formation marker but not the 
bone resorption marker in our current study suggests that 
there is an uncoupling of bone turnover favouring formation 
more than the resorption in response to mechanical 
stimulation. Similarly in the previously mentioned study of 
prepubertal boys a greater increase in bone formation than 
resorption marker was also observed. Studies have reported 
increased expression of osteoprotegerin [a factor affecting 
bone resorption] in serum in association with reduced 
bone resorption through the activation of the canonical 
wnt-signalling pathway through LRP5/624; however we did 
not measure OPG in this study, as we had not previously 
demonstrated a significant difference in OPG levels between 
baseline and day 8 following WBV in prepubertal boys18.
Soderpalm et al. studied the tolerability and effects of WBV 
on muscle and bone in six ambulatory children with Duchenne 
Muscular Dystrophy aged between 5-12 years. They did not 
find a significant change in bone mass or bone turnover 
markers. However a non-significant trend towards an 
increase in bone specific alkaline phosphatase was observed 
after 3 months of WBV, which returned to baseline, 3 months 
post discontinuation of WBV. Their study population differed 
to ours, having a significant muscle disease and also being 
treated with the steroid prednisolone and we did not measure 
alkaline phosphatase post vibration in our study to compare 
with Soderpalm’s results. However these results do suggest 
that the response to WBV of bone turnover markers may 
be transient and not sustained over long periods of time25. 
Kilebrant et al. studied the effects of WBV on bone mass, 
bone turnover markers and body composition in 19 children 
aged between 5 and 16 with severe motor disabilities who 
used wheelchairs for mobility, but also spent time each day 
in a standing frame. WBV was delivered 5-15 minutes per 
treatment twice a week for 6 months. All measurements 
were undertaken at baseline, 6 and 12 months. They found 
a significant increase in TBLH BMD and BMC after 6 months 
of WBV. There were no clear changes in any of the bone 
formation or resorption markers measured between baseline 
and 6 months; however, no “early” measurements i.e. within 
1-2 weeks of commencing WBV, were made26. There are 
no published studies of the acute response to vibration in 
children with bone diseases.
The results obtained in our study are consistent with 
Figure 3. CTX at baseline and post vibration.
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those from our studies of antenatal vitamin D depletion in 
a preclinical mouse model system. There we demonstrated 
that despite post-natal vitamin D repletion, the offspring 
of dams who had been made vitamin D deficient accrued 
substantially less bone in response to mechanical loading 
than the offspring of dams who were replete in vitamin D. 
These effects were apparent during growth affecting both 
cortical and trabecular bone and after growth had ceased 
affecting cortical bone accrual at skeletal maturity. It seems 
possible that this “programming” effect may also be operating 
in the human situation, given the results demonstrated here, 
and the observational data from other studies that suggest 
a positive association of maternal and early infant vitamin D 
status with later bone size and mass17. There are no similar 
previous experiments of this nature (i.e combining vitamin 
D depletion with mechanical loading) with which to compare 
our data.
Strengths and limitations
This is the first study to report the results of mechanical 
loading of bone in children exposed to high dose (1000 IU 
daily) vitamin D supplementation in pregnancy. The key 
strength of our study is the unique study cohort that has been 
randomised to vitamin D or placebo antenatally, combined 
with the novel technique of stimulating bone in a consistent 
way and measuring the response using serum markers of 
bone formation and resorption. 
The focus of the study was only to measure the change 
in two specific bone turnover markers (PINP and CTX) 
in response to loading and therefore we were unable to 
determine any mechanism that might link antenatal vitamin 
D supplementation with this response. Muscle strength, a 
determinant of bone mass, was not measured. This study was 
conducted in only 1 out of 3 MAVIDOS centers, thus sample 
size was relatively small with a limited number of subjects in 
the intervention group. Dietary calcium intake (grams/day) 
was significantly higher in the intervention group (p=0.04). 
The activity score (METs units) was significantly higher in the 
placebo group when compared with the intervention group 
(p=0.04). These could potentially have interacted with the 
effect of any prenatal programming on bone formation and 
resorption markers. However, failure to ascertain dietary 
and exercise data in nearly a third of participants means that 
drawing conclusions about potential interactions of such 
factors with the response to vibration is difficult. Equally 
adjusting for both dietary calcium and exercise at baseline 
had little influence on the change in PINP and CTX.
Conclusions
Our study demonstrates that children born to mothers who 
received vitamin D supplementation during pregnancy have a 
greater bone formation response to mechanical stimulation. 
This implies early life vitamin D supplementation increases 
the anabolic response of bone to mechanical loading in 
children. We suggest that supplementation of pregnant 
women with a higher dose of vitamin D may improve bone 
health in early childhood, which in turn may increase lifetime 
bone accrual and reduce the risk of developing osteoporosis 
and fragility fractures in later life as adults. Given the limited 
sample size, confirmation in a larger cohort is needed, along 
with prospective data collection on fractures. 
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